NIH ALS Conference: Clinical Research to Find the Pathogenesis and Cause of ALS

NIH ALS 会议：寻找 ALS 发病机制和原因的临床研究

• 批准号: 8129353
• 负责人: HIROSHI MITSUMOTO
• 金额: $ 2.5万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8129353
• 关键词: Adult; Amyotrophic Lateral Sclerosis; Animal Model; Animals; Biological Markers; Cessation of life; Characteristics; Clinical; Clinical Research; Clinical Trials; Collaborations; Development; Diagnosis; Disease; Disease Progression; Environmental Risk Factor; Epidemiologic Studies; Epigenetic Process; Failure; Familial Amyotrophic Lateral Sclerosis; Family member; Fostering; Funding; Funding Agency; Future; Genetic; Glare; Human; Inherited; International; Investigation; Journals; Knowledge; Lead; Left; Methodological Studies; Modeling; Molecular Biology; Molecular Genetics; Mus; Mutate; Neuraxis; Neurology; Neurosciences; Paper; Paralysed; Pathogenesis; Patients; Pharmaceutical Preparations; Physicians; Population; Positioning Attribute; Problem Solving; Publishing; Recommendation; Research; Research Personnel; Respiratory Failure; Riluzole; SOD1 gene; Scientist; Skeletal Muscle; Suggestion; Testing; Time; Tissues; Transgenic Mice; Uncertainty; United States National Institutes of Health; Variant; Work; base; design; effective therapy; genetic epidemiology; human disease; improved; innovation; interest; knowledge of results; lifestyle factors; meetings; nervous system disorder; patient oriented research; success; symposium

DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a devastating and enigmatic disease with no cure. The single approved, available medication, Riluzole, only modestly slows disease progression. Nearly 30 potential medications, developed based on diverse hypotheses, have been extensively tried in the past 20 years, but this has been without success. On the other hand, incredible progress in animal models, molecular biology and neuroscience has led to the identification of a number of hereditary causes of familial ALS and generated many exciting hypotheses in ALS. Nevertheless, there is still a glaring deficit in our knowledge of the pathogenesis and cause of ALS. Consequently, if we are to understand and effectively treat this disease, we need to further investigate the disease mechanisms and cause in our ALS patients. We strongly believe that the key to this mystery is likely to exist in the patients themselves. However, studying patients with ALS poses many challenges because 1) ALS is relatively rare (1 to 2 cases per 100,000 population), 2) given its rapid progression, there is little time for research after diagnosis, 3) patients are generally diagnosed late in adulthood, leaving few immediate family members for study, and 4) access to the central nervous system tissue is highly limited. Despite these limitations and tremendous methodological challenges, ALS physicians and physician-scientists are still in the best position to study the cause and pathogenesis of ALS directly in patients. Further, we need not only to find creative and innovative ways to investigate this disease, but also, to work with basic scientists as close partners. Therefore, we propose to hold a conference to energize clinical or patient-oriented research in ALS. We specifically aim to: 1) bring ALS physicians, physician-scientists and basic scientists together to discuss a focused topic, clinical research (not clinical trials); 2) review the current status of the pathogenesis and cause of ALS including clinical characteristics, biomarkers, epidemiology, and genetic and epigenetic studies, most of which are amenable to clinical research; 3) encourage physicians to collaborate with basic scientists in order to consider the feasibility of developing clinical research with the aim of discovering the cause(s) and pathogenesis of ALS. Further, we will discuss methodological and funding issues that must be overcome in order to move clinical research forward; and 4) publish the results and recommendations from the conference as a supplement or as a white paper in a major neurology journal. The meeting will be designed to allow for the open exchange of ideas, and will hopefully work out strategies for developing very active clinical research in the future. It is imperative that physicians and scientists realize that, more than ever before, there is a serious need for such collaboration in ALS. We strongly believe that this meeting will be a step forward to finding the pathogenesis and cause(s), and eventually, the cure for this dreaded disease, ALS. PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurological diseases with no cure. Its pathogenesis and cause are not yet established. We propose an NIH ALS Conference in which physicians and basic scientists, who both specialize in ALS, will come together and discuss how to facilitate and energize clinical research to find the pathogenesis and cause of ALS in the future. This will be an important step to lead to the cure for ALS.

肌萎缩侧索硬化症（ALS）是一种无法治愈的毁灭性和神秘的疾病。唯一批准的可用药物阿曲唑只能适度减缓疾病进展。在过去的20年里，基于不同的假设开发了近30种潜在的药物，但都没有成功。另一方面，在动物模型、分子生物学和神经科学方面取得了令人难以置信的进展，导致了对家族性ALS的许多遗传原因的鉴定，并产生了许多令人兴奋的ALS假说。然而，我们对ALS的发病机制和病因的认识仍然存在明显的不足。因此，如果我们要了解并有效治疗这种疾病，我们需要进一步研究ALS患者的疾病机制和原因。我们坚信，解开这个谜团的钥匙很可能就存在于患者自身。然而，研究ALS患者带来了许多挑战，因为1）ALS相对罕见（每10万人中有1至2例），2）鉴于其快速进展，诊断后几乎没有时间进行研究，3）患者通常在成年后期被诊断，几乎没有直系亲属可供研究，以及4）中枢神经系统组织的获取非常有限。尽管存在这些局限性和巨大的方法学挑战，ALS医生和医生科学家仍然处于直接研究患者ALS的病因和发病机制的最佳位置。此外，我们不仅需要找到创造性和创新性的方法来研究这种疾病，而且还需要与基础科学家作为密切的伙伴进行合作。因此，我们建议举行一次会议，以激励临床或以患者为导向的研究在ALS。我们的具体目标是：1）将ALS医生，医生科学家和基础科学家聚集在一起讨论一个重点话题，临床研究（非临床试验）; 2）回顾ALS的发病机制和病因的现状，包括临床特征、生物标志物、流行病学以及遗传学和表观遗传学研究，其中大多数适于临床研究; 3）鼓励医生与基础科学家合作，以考虑开展临床研究的可行性，目的是发现ALS的病因和发病机制。此外，我们将讨论方法和资金问题，必须克服，以推动临床研究向前发展;和4）发表的结果和建议，从会议作为补充或作为白色论文在一个主要的神经学杂志。这次会议的目的是允许开放的思想交流，并有望制定出战略，在未来发展非常活跃的临床研究。医生和科学家必须意识到，比以往任何时候都更需要在ALS中进行这种合作。我们坚信，这次会议将是向前迈出的一步，找到发病机制和原因，并最终治愈这种可怕的疾病，ALS。 公共卫生相关性：肌萎缩侧索硬化症（ALS）是最具破坏性的神经系统疾病之一，无法治愈。其发病机制和原因尚未确定。我们提议召开一次NIH ALS会议，专门研究ALS的医生和基础科学家将聚集在一起，讨论如何促进和激励临床研究，以找到未来ALS的发病机制和原因。这将是治愈ALS的重要一步。